Statin-ezetimibe vs PCSK9is: Which is better in ACS?In a systematic review and network meta-analysis (NMA), a statin-ezetimibe combination yields a more favourable LDL-C reduction and a positive trend in atherosclerotic plaque regression compared with PCSK9 inhibitors (PCSK9is) alone in individuals with acute coronary syndrome (ACS).
“The NMA yielded two critical, yet divergent, findings,” the researchers said. First, there was a statistically significant and superior LDL-C reduction with statin-ezetimibe compared with PCSK9is (odds ratio [ORs], 0.03 vs 1.00).
For the clinically pertinent endpoint of atherosclerotic plaque volume regression, there was no statistically significant difference between the combo regimen and PCSK9is (ORs, 0.75 vs 1.00). Although the point estimate favoured the former, the confidence interval was exceptionally wide (0.01–47.86), signifying profound imprecision and uncertainty, they noted.
“The cornerstone of improving outcomes [in ACS patients] is intensive lipid-lowering therapy (LLT) … [H]igh-intensity statins have long been the foundational therapy, but recent advances have revolutionized treatment paradigms,” the investigators said.
In one trial, a combination of rosuvastatin 10 mg and ezetimibe 10 mg was noninferior to rosuvastatin 20 mg alone for the primary composite endpoint of cardiovascular (CV) death, major adverse CV event, or nonfatal stroke (8.1 percent vs 8.7 percent; hazard ratio, 0.93) and led to fewer adverse drug reactions (4.8 percent vs 8.2 percent) over a median follow-up of 3.4 years. [The Lancet 2022;400:380-390]
PCSK9is have demonstrated their ability as powerful adjuncts to statin therapy in patients requiring greater LDL-C reduction. [JAMA 2016;316:2373; JACC Cardiovasc Imaging 2022;15:1308-1321; Cardiol Ther 2020;9:59-73; N Engl J Med 2018;379:2097-2107] “Despite their efficacy, critical uncertainties and challenges remain,” the investigators noted.
The team sought to evaluate two potent LLTs for their ability to promote plaque regression or modify plaque composition. Sixteen studies (n=95,549) provided a robust dataset for the NMA. The study populations reflected the target cohorts for intensive LLT, ie, older men with comorbidities (eg, hypertension, diabetes) who are at high risk for atherosclerotic CV disease. The researchers noted that the use of intravascular ultrasound provided high credibility to the primary imaging results. [ACC 2026, abstract 1475-128]
“The primary conclusion is that, while the statin-ezetimibe combination is significantly more effective at reducing LDL-C levels … this biochemical superiority does not translate into a statistically significant greater reduction in atherosclerotic plaque volume over an average follow-up of 52 weeks when compared directly with PCSK9is,” the researchers said.
“The clinical implications of these results are substantial, especially in an era focused on value-based healthcare,” they highlighted. “The unequivocal LDL-lowering supremacy of the generic statin-ezetimibe combo offers a compelling argument for its use as first-line intensive therapy for most patients requiring aggressive LDL-C reduction to halt atherosclerosis progression.”
The noninferiority of PCSK9is for plaque regression validates their vital role as a second-line treatment option for statin-intolerant patients or those who require additional LDL-C lowering to meet their personalized goals in addition to maximally tolerated oral therapy.
“The findings ultimately reinforce the principle that ‘lower is better for longer’ with regard to LDL-C and atherosclerosis, regardless of the mechanism used to achieve it. The goal of therapy should be to drive the LDL-C level as low as possible, as tolerated by the patient,” they said.
The researchers called for longer-term imaging studies and cost-effectiveness analyses to reinforce the findings.